ArticleOncology research2009
VEGF165 promotes the osteolytic bone destruction of ewing's sarcoma tumors by upregulating RANKL.
Article in Oncology research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy.Frontiers in immunology · 2021Review
- Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models.International journal of molecular sciences · 2020Review
- The endochondral bone protein CHM1 sustains an undifferentiated, invasive phenotype, promoting lung metastasis in Ewing sarcoma.Molecular oncology · 2017Article
- Roles of VEGF-Flt-1 signaling in malignant behaviors of oral squamous cell carcinoma.PloS one · 2017Article
- Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma.Frontiers in pharmacology · 2017Review
- Tumor-Associated Macrophages in Oncolytic Virotherapy: Friend or Foe?Biomedicines · 2016Review
- Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016Review
- Article
- Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.Journal of bone oncology · 2015Article
- Practical murine hematopathology: a comparative review and implications for research.Comparative medicine · 2015Review
- Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma.Frontiers in oncology · 2015Review
- Bisphosphonate therapy in pediatric patients.Journal of diabetes and metabolic disorders · 2014Review
- Bone sarcomas: from biology to targeted therapies.Sarcoma · 2012Article
- Macrophage infiltration predicts a poor prognosis for human ewing sarcoma.The American journal of pathology · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The purpose of this study was to determine whether vascular endothelial growth factor-165 (VEGF165) contributed to the osteolytic process in Ewing's sarcoma. VEGF165 induced osteoclast formation from murine bone marrow cells. Tartrate-resistant acid phosphatase (TRAP) staining demonstrated significantly fewer osteoclasts in VEGF-inhibited TC/siVEGF7-1 tumors compared to TC71 parental or TC/si-control tumors. Receptor activator NF-kappaB (RANKL), a critical osteoclastogenic factor, was decreased in TC/siVEGF7-1 cells. Incubation of these cells with recombinant VEGF165 upregulated RANKL in a dose- and time-dependent manner. The induction of (RANKL) by VEGF165 was also demonstrated in MC3T3-E1 mouse osteoblast cells and bone marrow stromal cells. This upregulation was transcriptionally mediated by an effect on the RANKL promoter. Both VEGF and EWS/FLI-1 increased RANKL promoter activity. Taken together, these data suggest that modulation of RANKL by VEGF165 may be one of the mechanisms responsible for the osteolytic process induced by Ewing's sarcoma cells. VEGF165 may, therefore, play an important role in modulating RANKL gene expression in the bone marrow microenvironment during the metastatic process, thereby contribution to tumor induced bone lysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.